The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 28, 2023

Filed:

Nov. 09, 2017
Applicants:

The Board of Regents of the University of Texas System, Austin, TX (US);

Pulmotect, Inc., Houston, TX (US);

The Texas A&m University System, College Station, TX (US);

Inventors:

Burton F. Dickey, Houston, TX (US);

Michael J. Tuvim, Houston, TX (US);

Scott E. Evans, Bellaire, TX (US);

Magnus Hook, College Station, TX (US);

David P. Huston, College Station, TX (US);

Margarita Martinez-Moczygemba, College Station, TX (US);

Brenton Scott, Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 9/00 (2006.01); A61K 31/7125 (2006.01); A61K 39/35 (2006.01); A61P 37/08 (2006.01); A61K 31/58 (2006.01); A61K 38/16 (2006.01); C12N 15/117 (2010.01); H04B 1/04 (2006.01); H04B 1/16 (2006.01); H04B 1/715 (2011.01); H04B 1/7156 (2011.01); H04B 1/40 (2015.01); H04B 1/713 (2011.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/35 (2013.01); A61K 31/58 (2013.01); A61K 38/164 (2013.01); A61P 37/08 (2018.01); C12N 15/117 (2013.01); H04B 1/04 (2013.01); H04B 1/16 (2013.01); H04B 1/40 (2013.01); H04B 1/713 (2013.01); H04B 1/715 (2013.01); H04B 1/7156 (2013.01); A61K 2039/55561 (2013.01); C12N 2310/315 (2013.01);
Abstract

Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.


Find Patent Forward Citations

Loading…